同仁堂國藥(03613.HK)中期純利升17.9%至2.67億港元
格隆匯8月6日丨同仁堂國藥(03613.HK)公佈,截至2021年6月30日止6個月,集團銷售收入為7.04億港元,同比上升24.1%;毛利為5.00億港元,同比上升28.5%;公司擁有人應占利潤為2.67億港元,同比上升17.9%;每股基本盈利0.32港元,不派中期股息。
於期內,集團制訂大品種戰略計劃,助力新營銷策略轉化及推動品牌戰略升級,以新營銷撬動市場潛在需求。集團以安宮牛黃丸及破壁靈芝孢子粉膠囊為重點培育產品,加強線上線下媒體的推廣力度,通過電視、紙媒、網媒平台等方式,投放同仁堂心腦血管系列產品廣吿,結合大品種產品特點,將健康信息傳遞給廣大消費者,擴大了同仁堂品牌的認知羣體,並提升了市埸佔有率。
2021年5月,於天貓香港平台開設的同仁堂旗艦店正式上線,集團配合天貓官方活動計劃及營銷日曆,策劃舉辦了開站慶、品牌日、包郵日、618年中慶等一系列活動,通過站內站外資源獲得大量線上店鋪曝光度,吸引眾多粉絲關注,銷量穩步提升,並居於同類型店鋪排名榜首。
集團將持續增強市場拓展力度,擴大市場宣傳維度,優化完善市場營銷策略,結合特殊時期本地市場及海外市場實際情況,制定更具同仁堂特色及更加符合各地消費文化、購物習慣的市場推廣方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.